As China Dives Into RWE, J&J Teams Up To Tackle Depression
Executive Summary
A new tie-up between J&J and a Singapore startup portends a new chapter for China drug development, using real world data and associated evidence, as China moves to clarify RWE regulations.
You may also be interested in...
Deal Watch: Altimmune Moves Into NASH With Purchase Of Spitfire
Currently focused on HBV, Altimmune gets preclinical NASH candidate that offers dual agonism of GLP-1 and glucagon receptors. Nimbus expands alliance with Celgene into IO, Merck & Co. partners with Skyhawk.
Otsuka, Click ‘Digital Therapeutic’ Alliance Aims At Novel Depression Option
“There’s an app for that” could take on added significance under a new alliance for a digital therapeutic for the treatment of depression, in which the partners hope the novel approach will take its place as an effective option among current drug and other cognitive therapies.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.